Coronado Biosciences is a clinical stage biopharmaceutical company focused on making cancer care better. How do we define better? We hope to make cancer care safer and more easily tolerated with improved outcomes.

At Coronado Biosciences, we in-license promising therapies during late pre-clinical study and shepherd them through the drug development process. Our approach centers on refining identified product candidates and choosing therapeutic areas that allow for rapid progress from pharm/tox studies, through IND, and into proof-of-concept clinical trials. This model allows us to maximize product development opportunities, minimize potential risks associated with drug discovery, research, and earlier-stage activities, and maximize value inflections for investors.

Our current drug candidates are based on related therapies with proven safety and biological activity in humans.

Key Management Personnel

RJ Tesi M.D. – President and CEO

• 15+ years biotech experience
• Previously at Cellerant Therapeutics and SangStat Medical Corporation

Elizabeth Moore – SVP Regulatory Affairs

• 20+ years of regulatory experience
• Previously at Tracon, Salmedix, Pfizer (PGRD), Agouron Pharmaceuticals, National Cancer Institute, NIH

Linda Rogers – VP Clinical Operations

• 30+ years of clinical operations experience
• Previously at SangStat Medical Corporation, Pharmacyclics, Berlex, Genentech, and Abbott

Peggy Wentworth, PhD – VP Development Operations

• 20+ years of drug development experience
• Previously at Chiron, Salmedix, Isis, Cytel, Epimmune and Xencor